Why is Glenmark Pharma falling/rising?

As of 22-Jul, Glenmark Pharmaceuticals Ltd. is currently priced at 2,154.25, reflecting a decrease of 33.25, or 1.52%. The stock has been underperforming recently, having fallen for three consecutive days with a total decline of 3.25%. Despite this short-term downturn, the stock has shown strong performance over the past month, with a 31.85% increase, and impressive returns over the year and three years, at 50.86% and 475.16%, respectively. The company has consistently delivered positive results, with a significant growth in profit after tax and a low debt to EBITDA ratio, indicating strong financial health. Additionally, high institutional holdings suggest confidence from knowledgeable investors, which may provide some support to the stock despite its recent price decline.
In the broader market context, Glenmark's recent performance contrasts with the benchmark, as it has underperformed the Sensex by 3.42% over the past week, while the Sensex itself has only decreased by 0.47%. This indicates that the stock's short-term challenges are more pronounced than the overall market trends. However, the rising investor participation, evidenced by a 49.71% increase in delivery volume, suggests that there is still interest in the stock, which may help stabilize its price in the near future. Overall, while Glenmark Pharmaceuticals is experiencing a decline in the short term, its strong fundamentals and historical performance may provide a foundation for recovery.